Global Market Size, Forecast, and Trend Highlights Over 2025-2037
In-vitro diagnostics for cardiology and neurology Market size was valued at USD 17.24 billion in 2024 and is set to exceed USD 52.23 billion by 2037, expanding at over 8.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of IVD in cardiology and neurology is evaluated at USD 18.54 billion.
The growth of the market can be attributed to the growing adoption of point-of-care testing devices to fuel the demand for in-vitro diagnostics tests, and increasing prevalence of chronic diseases across the globe. In 2019, approximately 18 million people in the world died from cardiovascular diseases, and about 9 million people from cancer, both of which are chronic diseases. Along with these, rising awareness levels regarding disease diagnosis, and rapidly surging geriatric population worldwide, as they are more prone to several disorders, are also expected to drive market growth in the forthcoming years. Furthermore, pharmaceutical companies are investing heavily on the development of condition-specific markers and tests, which in turn is projected to offer ample growth opportunities to the market in the near future.
In-vitro diagnostics for cardiology and neurology Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Adoption of Point-of-Care Testing Devices
- Increasing Prevalence of Chronic Diseases Across the Globe
Challenges
- High Cost of In-Vitro Diagnostics Instruments
In-vitro diagnostics for cardiology and neurology Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.9% |
|
Base Year Market Size (2024) |
USD 17.24 billion |
|
Forecast Year Market Size (2037) |
USD 52.23 billion |
|
Regional Scope |
|
In-vitro diagnostics for cardiology and neurology Segmentation
The market is segmented by product type into instruments, data management software, and reagents & consumables, out of which, the reagents & consumables segment is anticipated to observe robust growth in the global in-vitro diagnostics for cardiology and neurology industry. This can be accounted to the fact that recently developed reagents & consumables possess high precision and enable accurate diagnosis. Apart from these, rise in research and development activities to diagnose chronic disorders is also predicted to raise the demand for reagents in the future. Additionally, on the basis of end user, the hospitals segment is assessed to acquire the largest share during the forecast period owing to the huge amount of diagnostic testing required for supporting a clinical decision to enhance patient discovery, which is only possible in a hospital facility.
Our in-depth analysis of the market includes the following segments:
|
By Product Type |
|
|
By Technology |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportIn-vitro diagnostics for cardiology and neurology Industry - Regional Synopsis
Regionally, the global in-vitro diagnostics for cardiology and neurology market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Asia Pacific industry is set to dominate majority revenue share by 2037, attributed to growing investments by healthcare providers to improve the diagnostics infrastructure in the region. In addition, high need to maintain the rising burden of cardiological diseases is also expected to boost the market growth in the region in the coming years. Moreover, the market in North America is projected to grab the largest share during the forecast period owing to the high healthcare spending, increasing investments to improve molecular diagnostic devices, and strong presence of major market players in the region. As per the data provided by the Centers for Medicare and Medicaid Services, the healthcare spending in the United States grew 9.7 percent in 2020, reaching a value of USD 4.1 trillion or USD 12,530 per person.
Companies Dominating the In-Vitro Diagnostics for Cardiology and Neurology Landscape
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffman-La Roche Ltd
- Sysmex Corporation
- Siemens AG
- Becton, Dickinson, and Company
- DiaSorin S.p.A.
- Quest Diagnostics, Inc.
- Bio-Rad Laboratories, Inc.
- Abbott Laboratories
- Danaher Corporation
In the News
-
December 2021- Roche completed the purchase agreement or expanding PCR-test portfolio in the fight against new infectious diseases with its long-term partner TIB Molbiol.
-
November 2021- Thermo Fisher Scientific launched a new in-vitro diagnostics system that enables assay developers and clinical laboratories to accelerate molecular diagnosis growth.
Author Credits: Radhika Pawar
- Report ID: 3849
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
